Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/DMT/Equity and Ethics

DMT for Equity and Ethics

3 papers and 0 clinical trials exploring dmt as a treatment for equity and ethics.

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
IndicationApproximately 1 in 4 adults experience mental health disorders annually worldwide.

Equity and Ethics

Equity and ethics in psychedelic research is a vital and complex topic, addressing the need for fair access and representation in clinical trials, as well as the stewardship of traditional knowledge. The involvement of Indigenous communities, who have historically used these substances, must be safeguarded against exploitation as the field matures.

Full Equity and Ethics profile

Academic Research

3 papers
Paywallmeta

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

This systematic review and meta‑analysis of 214 studies (3,504 participants with analysable adverse‑event data) found that high‑dose classic psychedelics were generally well tolerated in clinical/research settings, with serious adverse events occurring mainly in ~4% of participants who had preexisting neuropsychiatric disorders and no reports in contemporary trials of suicide, persistent psychotic disorder or hallucinogen‑persisting perception disorder. Common non‑serious adverse events (headache, anxiety, nausea, fatigue, dizziness) had similar prevalences for psilocybin and LSD, but substantial heterogeneity and limited systematic adverse‑event monitoring across studies highlight the need for improved pharmacovigilance.

Published
December 1, 2024
Journal
JAMA Psychiatry
Authors
Hinkle, J. T., Graziosi, M., Nayak, S., Yaden, D. B.
Paywallmeta

Research abuses against people of colour and other vulnerable groups in early psychedelic research

This review of early psychedelic studies (the 50s-70s, s=48) finds that most (77%) would not pass ethical review today. The errors made in early research were extensive dosing, lack of consent, inadequate setting, and lack of scientific hypotheses. The authors make restorative justice and cultural competency suggestions.

Published
July 12, 2021
Journal
Journal of Medical Ethics
Authors
Strauss, D., de la Salle, S., Sloshower, J. A., Williams, M. T.
Paywallindividual

Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings

Using wireless EEG and psychometric questionnaires in 35 experienced participants in natural settings, inhaled N,N-dimethyltryptamine acutely reduced alpha (8–12 Hz) power across the scalp while increasing delta (1–4 Hz) and gamma (30–40 Hz) power, with gamma global synchrony and metastability rising as alpha measures fell. Gamma power increases correlated with mystical-type subjective reports, suggesting candidate EEG markers of such experiences and endorsing the value of field research on psychedelics.

Published
February 10, 2021
Journal
Journal of Psychopharmacology
Authors
Pallavicini, C., Cavanna, F., Zamberlan, F., de la Fuente, L. A., Ilksoy, Y., Perl, Y. S., Arias, M., Romero, C., Carhart-Harris, R. L., Timmermann, C., Tagliazucchi, E.

Clinical Trials

0 trials

No clinical trials have been tagged with both DMT and Equity and Ethics yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all DMT papers Search all Equity and Ethics trials Full DMT profile Full Equity and Ethics profile